Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Zemljic, F.
Correlation of lipid signatures with multidrug resistance in CIC-DUX4 sarcoma
based on a novel patient-derived model
Humanmedizin; [ Diplomarbeit ] Medizinische Universität Graz; 2023. pp. 57
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Liegl-Atzwanger Bernadette
- Rinner Beate
- Altmetrics:
- Abstract:
- CIC-DUX4 sarcoma is a rare subtype of sarcoma characterized by a recurrent chromosomal translocation resulting in the fusion of the CIC and DUX4 genes. The study of lipid metabolism in CIC-DUX4 sarcomas can provide valuable insights into the metabolic alterations underlying the pathogenesis of this malignancy and potentially guide the development of targeted therapeutic approaches. In this study, we aimed to characterize the lipid profile of the CIC-DUX4 sarcoma cell line MUG CIDUS and compare it with the reference EWING sarcoma cell line MHH-ES-1 (EWSR1-FLI1 fusion). Lipidomic analysis was performed using mass spectrometry-based techniques on lipid extracts obtained from both cell lines. Comprehensive profiling allowed the identification and quantification of various lipid species, including phospholipids, sphingolipids, and cholesterol esters. The results revealed significant differences in the lipid profiles between the CIC-DUX4 sarcoma cell line MUG CIDUS and the reference cell line MHH-ES-1. Specifically, alterations were observed in the levels of specific lipid species, suggesting dysregulation in lipid metabolism pathways associated with the CIC-DUX4 fusion gene. These findings provide evidence for distinct lipid signatures in CIC-DUX4 sarcoma, potentially contributing to the understanding of its unique pathogenesis. Furthermore, the comparative analysis allowed for the identification of lipid markers that distinguish the CIC-DUX4 sarcoma cell line from the reference cell line. These lipid markers may serve as potential targets for the development of therapeutic strategies specifically designed to disrupt lipid metabolism in CIC-DUX4 sarcoma. In conclusion, this study provides novel insights into the lipid profile of the CIC-DUX4 sarcoma cell line MUG CIDUS, highlighting significant differences compared to the reference cell line MHH-ES-1. These findings contribute to the understanding of the metabolic alterations associated with CIC-DUX4 sarcoma and may have important implications for the development of targeted therapies. Further investigation into the functional significance of the identified lipid species and their role in the pathogenesis of CIC-DUX4 sarcoma is necessary.